Status:
COMPLETED
Assessing Cosopt Switch Patients
Lead Sponsor:
Pharmaceutical Research Network
Conditions:
Ocular Hypertension
Open-Angle Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
Eligibility Criteria
Inclusion
- adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
- the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
- visual acuity should be 20/200 or better in each eye
Exclusion
- contraindications to study drugs
- anticipated change in systemic hypotensive therapy during the trial
- use of any corticosteroids by any route in the three months immediately prior to Visit 2
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00273442
Start Date
November 1 2005
End Date
April 1 2007
Last Update
November 19 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock Eye Clinic
Little Rock, Arkansas, United States, 72205
2
Omni Eye Services
Atlanta, Georgia, United States, 30342
3
Midwest Eye Center
Bourbonnais, Illinois, United States, 60914
4
Mark J. Weiss, MD
Tulsa, Oklahoma, United States, 74104